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Abstract
Background: Patient financial incentives ("incentives”) have been widely used to promote chlamydia screening
uptake amongst 15-24 year olds in England, but there is scarce evidence of their effectiveness. The objectives of
the study were to describe incentives used to promote chlamydia screening in Primary Care Trusts (PCTs) in
England and to evaluate their impact on coverage and positivity rate.
Methods: PCTs that had used incentives between 1/1/2007 and 30/6/2009 (exposed) were matched by socio-
demographic profile and initial screening coverage with PCTs that had not (unexposed). For each PCT, percentage
point change in chlamydia screening coverage and positivity for the period before and during the incentive was
calculated. Differences in average change of coverage and positivity rate between exposed and unexposed PCTs
were compared using linear regression to adjust for matching and potential confounders.
Results: Incentives had a significant effect in increasing average coverage in exposed PCTs (0.43%, CI 0.04%-0.82%).
The effect for voucher schemes (2.35%) was larger than for prize draws (0.16%). The difference was greater in
females (0.73%) than males (0.14%). The effect on positivity rates was not significant (0.07%, CI -1.53% to 1.67%).
Conclusions: Vouchers, but not prize draws, led to a small absolute but large relative increase in chlamydia
screening coverage. Incentives increased coverage more in females than males but had no impact on reported
positivity rates. These findings support recommendations not to use prize draws to promote chlamydia screening
and contribute to the evidence base of the operational effectiveness of using patient incentives in encouraging
public health action.
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Background
Chlamydia trachomatis is the most common sexually
transmitted infection (STI) in England and the overall
prevalence is estimated to be about 5% in the general
population under 20 years of age [1]. The National
Chlamydia Screening Programme (NCSP) was estab-
lished in 2003 to target all 15-24 year olds in England to
help prevent its potentially serious health complications
[2] and to reduce onward transmission.
Patient financial incentives (“PFIs”) have been used for
a range of intended health behaviour changes [3,4] and
t h e r ei ss o m ee v i d e n c eo fe f f e c ti ns i m p l eb e h a v i o u r
changes such as attending a meeting. However, they
were found much less effective to achieve more complex
and longer term changes in behaviour [4]. Incentives
have been widely used to increase chlamydia screening
coverage in England even though there is scarce evi-
dence of their effect on screening coverage or the rate
of chlamydia positivity [4-6]. There is also no evidence
on how these schemes may affect the age and sex com-
position of the population accepting screening.
T h ea i mo ft h i ss t u d yw a st od e s c r i b et h ef i n a n c i a l
initiatives schemes in England and to evaluate their
impact among 15-24 year olds by comparing chlamydia
screening coverage and positivity rate changes in Pri-
mary Care Trusts (PCTs) that had or had not used
incentives. We also compared the effect different
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those accepting screening.
Methods
Definition of patient financial incentives
Financial incentives were defined as any goods (monetary
or non-monetary) exchanged with a patient against the
desired action (chlamydia screen). The acquisition of
goods not depending on the desired action (e.g. handing
out tokens during outreach events) was excluded. PFI
schemes had to cover the majority of the PCT area.
All PFI schemes between 1
st January 2007 and 30
th
June 2009 were described (n = 65). The analysis of these
schemes was limited to prize draw and voucher schemes
(n = 46) that could be matched (n = 42) with PCTs that
had not used these schemes. Incentives based on tokens
with items of negligible monetary value (e.g. sweets, con-
doms, panties, n = 19) were excluded from this analysis
due to large variations in how these schemes operated.
Data sources
The Central Office of Information (COI) carried out a
national survey of PCTs’ use of PFI and health promotion
activities in April 2009 (response rate 75%). Information
from this survey was used to identify PCTs which had or
had not used incentives.
Telephone interviews with PCT screening leads were
conducted in September and October 2009 using a semi-
structured questionnaire to gather detailed information
on any incentive schemes and major health promotion
activities including mass mail-outs carried out during the
period of interest. We also confirmed that all schemes
had had safeguards against double-testing or providing
inappropriate samples. We interviewed screening leads
from all 46 PCTs which used incentives (as identified by
the COI survey) as well as PCTs where inadequate or
incomplete information was available from this survey.
Of the 84 PCTs included in the matched analysis,
73 (87%) were interviewed. Eleven unexposed PCTs were
not interviewed as the information from the COI survey
was deemed to be of sufficient quality. All PCTs selected
for telephone interviews were successfully contacted. We
further validated information on the incentive schemes
and other relevant health promotion campaigns using
routinely collected data from the NCSP.
Chlamydia screening coverage and positivity rates
Screening coverage and positivity were calculated using
routine data collection from the NCSP. For each chlamydia
screen reported to the NCSP there is additional informa-
tion on test result, and socio-demographic data. These data
are collated centrally by the NCSP and used to ascertain
the numbers and demographic characteristics of those
screened.
Chlamydia testing coverage rates per quarter for 15-24
year olds were calculated from the number of screens
among residents of a PCT using 2007 mid-year popula-
tion estimates from the Office of National Statistics
(ONS) as the denominator. Positivity was calculated as
the number of positive screens per total screens in a
quarter.
Our analysis was restricted to opportunistic screening;
persons tested for clinical reasons (4.8% of the data sub-
mitted to the NCSP) were excluded. Screens performed
in prisons or military settings (4%) were also excluded.
Equivocal, inhibitory or insufficient test results (2.6%)
were excluded from the positivity analysis. Data on
exposure, outcome and potential confounders was com-
plete. Screens returned with missing age or sex were
excluded from all analyses (complete case analysis).
Statistical analysis
For each PCT, we calculated the percentage point
change in chlamydia screening coverage and positivity
in the period before and during the incentive. We esti-
mated the difference in average change of the coverage
and the positivity rate between PCTs that had (exposed)
and had not used incentives (unexposed). The analysis
examined the effect on coverage and positivity over two
consecutive quarters: the quarter during which the PCT
started to use a PFI, and the quarter immediately prior
to the introduction of the PFI. Time periods used to cal-
culate changes were always the same within a matched
pair of PCTs, but varied between pairs.
PCTs which had employed incentives were matched to
unexposed PCTs by choosing the ones with the most
similar screening coverage in the quarter prior to the
PFI from the same ONS health area supergroup (clus-
ters of socio-demographically similar areas) [7]. A 1:1
matching was performed; PCTs which used more than
one PFI could be matched more than once if schemes
were more than six months apart. The PCT-pairing was
kept for all analyses. Percentage point changes in
screening and positivity rates were analysed at PCT
level.
A single variable analysis was performed. We differ-
enced the percentage point change of an exposed and
unexposed pair and then averaged these differences. The
analysis of changes in coverage and positivity were per-
formed in the same fashion, using paired t-tests.
Multivariable analysis used linear regression on obser-
vations for each PCT, and potential confounders were
considered and included if they were thought to affect
the comparison between exposed and unexposed PCTs.
We investigated the potential difference in the effect of
prize draws and voucher incentives by using an expo-
sure variable with 3 categories (“prize draw”, “voucher”
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sex was to investigate the potential difference between
the effect on females compared to males, and the effect
on 15-19 year olds compared to 20-24 year olds. We
divided the data for each PCT between four observa-
tions - one for each combination of sex and age group.
We always allowed for the pairing by controlling for a
variable that identifies each PCT-pair.
All analyses were performed using MS Excel XP and
Stata 11 (Stata Corporation, College Station, TX). Dif-
ferences in absolute change from baseline are presented
as recommended by the Cochrane guidelines [8].
Results
Description of patient incentive schemes
Forty-six of the 152 PCTs in England had used a total of
65 PFI schemes to increase chlamydia screening cover-
age between January 2007 and June 2009. Twenty-nine
P C T sh a du s e ds u c has c h e m eo n c e ,1 5t w i c ea n dt w o
three times. The majority of schemes (62%; 40/65) were
prize draws, which offered rewards ranging in value
from a £50 voucher to a £2000 holiday for four (Table
1). The remaining schemes used either tokens (29%; 19/
65) or vouchers (9%; 6/65), which ranged in value from
£5 to £10. Most incentives were delivered through out-
reach work (55%); with smaller proportions using postal
deliveries (25%), clinical services (9%) or other means
(11%). The use of PFI schemes by PCTs in England has
increased from an average of 2.5 schemes per quarter in
2007 to 13 per quarter in the first six months of 2009
(Table 1).
Characteristics of matched PCTs
Forty-two of the 46 prize-draw and voucher schemes were
matched to unexposed PCTs for coverage and ONS super-
group. We excluded four schemes from the analysis
because it was not possible to identify suitable matches
from the same ONS supergroup and time. The demo-
graphic characteristics (e.g. population size or index of
multiple deprivation, IMD) and NCSP activity (e.g. screen-
ing rates in the quarters before the incentive and service
activities) were very similar in the exposed and unexposed
PCTs (Table 2).
Difference in screening coverage
Screening coverage increased in both exposed and unex-
p o s e dP C T s( F i g u r e1 )a n di na l l8 4P C T st h ea v e r a g e
coverage in the quarter before a PFI was 2.3%. A single
variable analysis demonstrated that unadjusted rate
changes were more pronounced in PCTs which used
incentives (1.08%, CI 0.48% to 1.68%) compared to those
that had not (0.41%, CI 0.003% to 0.82%, Figure 1). The
average difference between paired PCTs (0.67%, CI 0.1%
to 1.24%) was significant (paired t-test p = 0.02).
The screening rate difference was more pronounced in
voucher schemes compared to prize draws (2.35% vs.
0.16%), and in females compared to males (0.73% vs.
0.14%). Further analysis of voucher schemes found sig-
nificant effects in females (3.18%) and to a lesser extent
in males (1.55%).
Further analysis considered the predominant setting
where the PFI was offered.
For prize draws we did not find any evidence for effect
modification by setting in the regression model (p =
0.15). Whilst based on a small sample (n = 6), there was
some evidence for effect modification for voucher
schemes by setting (p = 0.02), but not for the value of the
vouchers (p = 0.36, Table 3).
We found no evidence for effect modification by age
group (15-19 or 20-24, p =0 . 8 1 ) ,o rn u m b e ro fm o n t h s
that the PFI was operational in a quarter (p =0 . 5 ) .W e
found no significant effect of major health promotion
campaigns (p = 0.3) or mail-shot campaigns during the
period of the PFI (p = 0.4) on differences in coverage rates.
Table 1 Description of patient financial incentive
schemes used by PCTs to promote chlamydia testing,
January 2007-June 2009 (n = 65)
Overview of patient financial incentives
Prize draws 40 61.5%
Wii 17 42.5%
i-Pod 8 20.0%
Shopping voucher 5 12.5%
Holiday 6 15.0%
Other prizes 4 10.0%
Vouchers 6 9.2%
value £5-9 33.3%
value £10 4 66.7%
Tokens 19 29.2%
Primary setting of administering scheme
postal 16 24.6%
prize draw 13 81.3%
voucher 2 12.5%
tokens 1 6.3%
outreach 37 56.9%
prize draw 21 56.8%
voucher 1 2.7%
tokens 15 40.5%
clinical services 6 9.2%
prize draw 2 33.3%
voucher 1 16.7%
tokens 3 50.0%
other 6 9.2%
Period of schemes
2007 10 15.4%
2008 29 44.6%
2009 26 40.0%
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In all 84 PCTs the average positivity before a PFI was
7.24%. Overall there was lit t l ec h a n g ei np o s i t i v i t y
between observed quarters (0.12% CI -0.52% to 0.76%).
Employing the same matched pairs, the positivity rate
change was 0.26% (CI -0.69% to 1.20%) and -0.01% (CI
-0.91% to 0.89%) for unexposed and exposed PCTs
respectively.
Adjusting for IMD quintile, the average difference in
percentage point change between exposed and unex-
posed PCTs was small (0.07%, CI -1.53% to 1.67%) and
not significant (p =0 . 9 ) .W ef o u n dn oe v i d e n c ef o r
effect modification by the type of incentive scheme (p =
0.7). Differences in positivity changes were 0.17% (CI
-1.52% to 1.87%) and -0.55% (CI -4.33% to 3.23%) for
prize draw and voucher schemes respectively.
We found no evidence for effect modification by age
(p =0 . 7 )o rs e x( p = 0.5). The average difference in per-
centage point change was -0.08% (CI -1.96% to 1.8%, p =
0.9) and 0.22% (CI -1.65% to 2.09%, p = 0.8) for 16-19 and
20-24 years respectively. The average difference in percen-
tage point change was -0.3% (CI -2.1% to 1.6%, p =0 . 8 )
and 0.4% (CI -1.5% to 2.3%, p = 0.6) for males and females
respectively.
Discussion
We present the results of a national comparative study
on the effect of incentives on chlamydia screening cov-
erage and positivity rates. We found that voucher
schemes significantly increased screening coverage and
Table 2 Characteristics of matched PCTs (n = 42 pairs)
Exposed PCTs Unexposed PCTs P value
eligible PCT population
average 41,267 46,883 0.38
smallest 15,600 18,200
largest 86,000 152,000
Ave. proportion of females 15-19 24.2% 24.1% 0.93
Ave. proportion of females 20-24 24.4% 24.5% 0.93
Ave. proportion of males 15-19 25.6% 25.6% 0.94
Ave. proportion of males 20-24 25.8% 25.8% 0.95
IMD* rank (of 152 PCTs)
average 80 76 0.61
worst 7 6
best 130 149
Average screens in the quarter before incentive
Number 954 1,040 0.63
Range 11 - 2793 22 - 4497
Rate (per population of 15-24 olds) 2.37% 2.29% 0.77
Year screening programme established
2003-2005 15 9
2005-2007 5 18
2007-2008 22 15 0.01
Number of PCTs with mail-outs
Any mail-out 2007-2009 15 15 1.00
Mail-outs during incentive 11 8 0.43
*IMD (index of multiple deprivations) is a composite area deprivation index commonly used by the Office of National Statistics and other authorities in the UK. It
currently consists of seven domains, measuring income, employment, health, education, environment, crime and housing in a small area
P values were calculated for differences between exposed and unexposed PCTs using t-test for continuous variables and c
2 tests for proportions
Figure 1 Average Chlamydia screening coverage in exposed
and unexposed PCTs in the quarter before and during the
incentive time. Bars depict 95% confidence intervals In the
multivariable analysis we adjusted for the deprivation of the PCT
(IMD quintile) (Table 3). Adjusting for these variables, the average
screening rate change was 0.43% greater in PCTs which had used
incentives compared to those that had not (p = 0.03).
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dent of age. Prize draw schemes did not significantly
increase coverage in our study. The study did not find
any evidence of an effect on positivity rates, either over-
all or by age, sex or type of scheme, and this could
imply that the schemes do not lead to a substantial self-
selection of lesser risk individuals.
The only randomised control trial, conducted in a single
GP practice, did not observe any significant effect of vou-
chers on screening coverage [6]. Conversely, a recent
quasi-experimental study amongst tertiary students in Aus-
tralia found an effect of cash incentives on screening rates
[9]; but intervention arms were not clearly defined and
independent. Our findings of a significant effect of voucher
schemes is based on observational evidence from a few
schemes (n = 6). The larger overall effect sizes of voucher
schemes could reflect a higher perceived value of vouchers
compared to a prize draws, in keeping with the literature
[10-12]. Incentives using higher value vouchers seemed to
increase screening coverage, although not statistically sig-
nificantly (p = 0.4). However, the majority (86%) of incen-
tives evaluated in this study were prize draws and no
significant impact was demonstrated for these.
A significant decline in chlamydia prevalence can only
be achieved with high screening coverage and partner
management [13] and cost-effectiveness depends on
screening rates [14]. National policy aims are to increase
screening coverage to 35-50% per year in the medium
term [15]. The study covered the early period of the
NCSP (2007-2009) when many PCTs were establishing
local programmes and coverage achieved up to 12.5% in
our study PCTs, similar to national coverage [14]. The
observed 0.43% overall increase in coverage reported by
those PCTs using incentives represents an 18% relative
change and an average of 177 more screens per quarter,
ranging from 80 more screens in prized draws to 600 in
schemes using vouchers. These increases may have
appeared attractive in the early stages of the programme.
However, recent coverage rates are much higher (25% in
October-December 2010) [14] and such numbers may
appear less important in achieving high coverage in the
population and it is possible that incentives will have les-
ser impact at higher coverage rates.
Although some studies have shown that incentives can
be effective [3], currently NCSP does not recommend
incentives outside research arrangements [16], based on a
lack of evidence of their effectiveness [5,6] and concerns
around sustainability and ethics. The majority of incen-
tives in this study were conducted in non-clinical settings
such as outreach, and these settings have lower positivity
Table 3 Linear regression model of the difference in average percentage point change in screening coverage between
exposed and unexposed PCTs
Number of PCT Pairs Difference in average % change 95% Conf. interval P value P value (Effect modif.)
Any financial incentive 42 0.43% (0.04; 0.82) 0.03
Males 42 0.14% (-0.29%; 0.57%) 0.5
Females 42 0.73% (0.30%; 1.17%) 0.001 0.002
Prize draw 36 0.16% (-0.22%; 0.54%) 0.4
Vouchers 6 2.35% (1.55%; 3.14%) <0.0001 <0.0001
Prize draw in males 36 -0.05% (-0.47%; 0.38%) 0.8
Prize draw in females 36 0.37% (-0.06%; 0.80%) 0.09 0.03
Vouchers in males 6 1.55% (0.63%; 2.46%) 0.001
Vouchers in females 6 3.18% (2.25%; 4.11%) <0.0001 0.0005
Prize draw via outreach 19 0.14% (-0.40%; 0.68%) 0.606
Prize draw via post 11 0.16% (-0.39%; 0.71%) 0.57
Prize draw via clinic 2 1.58% (0.24%; 2.92%) 0.021
Prize draw via other 4 0.03% (-0.99%; 1.05%) 0.95 0.15
Voucher via outreach 1 3.15% (1.11%; 5.20%) 0.003
Voucher via post 2 3.66% (2.24%; 5.08%) <0.0001
Voucher via clinic 1 2.24% (0.25%; 4.23%) 0.027
Voucher via other 2 1.10% (-0.13%; 2.34%) 0.08 0.02
£5-9 Voucher 2 -0.66% (-2.22%; 0.9%) 0.4
£10 Voucher 4 2.65% (1.70%; 3.59%) <0.0001 0.36
The above is from a number of different models of screening coverage used in the analysis. The results are adjusted for the IMD quintile of the PCT and the
pairing of the analysis. P Values in the first column are a test of whether the effect of the PFI is different from zero. P Values in the second column (effect
modification) are a test of whether the effect of the PFI varies by the type of PFI (or by gender). Both significance tests are Wald tests.
We explored but found no evidence for effect modification by age group or by the length of time an incentive was run in a quarter affected by the PFI (1, 2 or 3
months). There was also no significant effect of health promotion campaigns or “simultaneous mail-out” (whether or not a mail-out was undertaken to promote
an incentive).
All differences are between the average of PCTs with a particular sort of incentive and the average of PCTs without an incentive.
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incentives are unlikely to provide a sustainable and cost
effective addition to the strategic direction of focussing on
core community services and aligning screening with
health promotion [15]. In addition, whilst probably not
coercive, incentives may have other unintended conse-
quences, such as undermining patient-doctor relationships
and patients’ choices, while sustainability is debatable and
controversy exists around the ethics of paying patients to
adopt healthy behaviours amongst healthcare professionals
[3,11,12,18] and the public [19].
Across all age-strata, there is evidence of a moderate
effect of financial incentives on simple behaviours, such as
attending meetings [20], but little impact on more com-
plex and sustained behaviour changes like smoking cessa-
tion or weight loss [21,22]. The use of incentives in sexual
health interventions has resulted in increased participation
rates [22-25], but failed to improve sexual health outcomes
[22,26]. However, incentives may have a role in overcom-
ing barriers (e.g. norms and attitudes) to chlamydia
screening in young people (aged 15-24) [27-29]. To
achieve high levels of screening coverage will require com-
plex rather than simple behaviour changes. Our findings
of a small absolute overall effect is broadly consistent with
the literature on complex behaviour changes [4].
The results from this observational study have evaluated
efficiently and inexpensively the impact of all schemes
during a 2 1/2 year period in England. Although we
believe that bias and confounding is minimal, our observa-
tional findings will need to be confirmed in a trial. The
number of voucher schemes was limited by their natural
occurrence and may be too small to give conclusive
results. The study was based on analyses of the NCSP
database which contains all NCSP screening returns, but
not those performed by other providers (i.e. those not
registered and reporting to the NCSP). However, almost
all incentives were coordinated by PCTs and/ or local
NCSP screening coordinators who maintained the record
for screening and reward. The relevance of these non-
NCSP screens in this context is therefore probably small.
Misclassification of the PCTs with respect to the use of
incentives is possible, but we believe unlikely. Information
on financial incentive schemes and possible confounders
such as other major PCT level activities was collected
through a national marketing survey conducted by the
COI. It is possible that some health promotion activities
or mail-outs may have been missed in this study. However,
this information was validated not only by telephone inter-
views with all PCTs who reported using incentives as well
as the majority of control PCTs, but also with other readily
available data from the NCSP. If exposure misclassification
did occur, it would be most likely to be the misclassifica-
tion of an exposed PCT as an unexposed PCT, leading to
an underestimation of the effect of the incentive.
Conclusions
In conclusion, we present the first national study of the
effectiveness of incentives in chlamydia screening. The
observational results should however be confirmed with
a trial. Incentives have been used in a wide variety of
contexts and our study adds to the discussion about
their effectiveness beyond the immediate NCSP context.
Based on our findings, prize draws are ineffective to
increase screening uptake and further research needs to
establish whether vouchers may play a role.
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